Design, synthesis, and enzymatic evaluation of multisubstrate analogue inhibitors of Escherichia coli thymidine phosphorylase

Journal of Medicinal Chemistry

Volumn 43, Issue 5, 2000, Pages 971-983

  Esteban Gamboa, Antonio ^a   Balzarini, Jan ^b   Esnouf, Robert ^b   De Clercq, Erik ^b   Camarasa, María José ^a   Pérez Pérez, María Jesús ^a  

^a INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; THYMIDINE PHOSPHORYLASE;

ARTICLE; COMPETITIVE INHIBITION; DRUG STRUCTURE; ENZYME INHIBITION; ESCHERICHIA COLI;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG DESIGN; ENZYME INHIBITORS; ESCHERICHIA COLI; KINETICS; MODELS, MOLECULAR; PHOSPHONIC ACIDS; PYRIMIDINONES; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY; THYMIDINE; THYMIDINE PHOSPHORYLASE; URACIL;

EID: 0034624754     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9911377     Document Type: Article

References (43)

1. Desgranges, C.; Raz̧aka, G.; Rabaud, M.; Bricaud, H.; Balzarini, J.; De Clercq, E. Phosphorolysis of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BvdU) and other 5-substituted-2'-deoxyuridmes by purified human thymidine phosphorylase and intact blood platelets. Biochem. Pharmacol. 1983, 32, 3583-3590.
2. Usuki, K.; Sara, J.; Waltenberg, J.; Miyazono, K.; Pierce, G.; Thomason, A.; Heldin, C. H. Platelet-derived endothelial cell growth factor has thymidine phosphorylase activity. Biochem. Biophys. Res. Commun. 1992, 184, 1311-1316.
3. Sumizawa, T.; Furukawa, T.; Haraguchi, M.; Fukui, K.; Takeyasu, A.; Ishizawa, M.; Yamada, Y.; Akiyama, S. Thymidine phosphorylase activity associated with platelet-derived endothelial cell-growth factor. J. Biochem. 1993, 114, 9-14.
4. Haraguchi, M.; Miyadera, K.; Uemura, K.; Sumizawa, T.; Furukawa, T.; Yamada, K.; Akiyama, S.; Yamada, Y. Angiogenic activity of enzymes. Nature 1994, 368, 198.
5. Moghaddam, A.; Zhang, H. T.; Fan, T. P.; Hu, D. E.; Lees, V. C.; Turley, H.; Fox, S. B.; Gatter, K. C.; Harris, A. L.; Bicknell, R. Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 998-1002.
6. Miyadera, K.; Sumizawa, T.; Haraguchi, M.; Yoshida, H.; Konstanty, W.; Yamada, Y.; Akiyama, S. Role of thymidine phosphorylase activity in the angiogenic effect of platelet-derived endothelial cell-growth factor/thymidine phosphorylase. Cancer Res. 1995, 55, 1687-1690.
7. Griffiths, L.; Stratford, I. J. Platelet-derived endothelial cell-growth factor thymidine phosphorylase in tumour growth and response to therapy. Br. J. Cancer 1997, 76, 689-693 and references therein.
8. Toi, M.; Hoshina, S.; Taniguchi, T.; Yamamoto, Y.; Ishitsuka, H.; Tominaga, T. Expression of platelet-derived endothelial cell-growth factor/thymidine phosphorylase in human breast cancer. Int. J. Cancer 1995, 64, 79-82.
9. Takebayashi, Y.; Akiyama, S.; Akiba, S.; Yamada, K.; Miyadera, K.; Sumizawa, T.; Yamada, Y.; Murata, F.; Aikou, T. Clinico-pathological and prognostic significance of an angiogenic growth factor, thymidine phosphorylase, in human colorectal carcinoma. J. Natl. Cancer Inst. 1996, 88, 1110-1117.
10. Imazano, Y.; Takebayashi, Y.; Nishiyama, K.; Akiba, S.; Miyadera, K.; Yamada, Y.; Ohi, Y. Correlation between thymidine phosphorylase expression and prognosis in human renal cell carcinoma. J. Clin. Oncol. 1997, 15, 2570-2578.
11. Matsushita, S.; Nitanda, T.; Furukawa, T.; Sumizawa, T.; Tani, A.; Nishimoto, K.; Akiba, S.; Miyadera, K.; Fukushima, M.; Yamada, K.; Yoshida, H.; Kanzaki, T.; Akiyama, S. The effect of thymidine phosphorylase inhibitor on angiogenesis and apoptosis in tumors. Cancer Res. 1999, 59, 1911-1916.
12. Langen, P.; Etzold, G.; Bärwolff, D.; Preusel, B. Inhibition of thymidine phosphorylase by 6-aminothymine and derivatives of 6-aminouracil. Biochem. Pharmacol. 1967, 16, 1833-1837.
13. Balzarini, J.; Esteban-Gamboa, A.; Esnouf, R.; Liekens, S.; Neyts, J.; De Clercq, E.; Camarasa, M. J.; Pérez-Pérez, M. J. 7-Deazaxanthine, a novel prototype inhibitor of thymidine phosphorylase. FEBS Lett. 1998, 438, 91-95.
14. There has also been a symposium report on 7-deazaxanthine derivatives as TPase inhibitors. Hirota K.; Sawada, M.; Sajiki, H.; Sako, M. Synthesis of 6-aminouracils and pyrrolo[2,3-d]-pyrimidine-2,4-diones and their inhibitory effect on thymidine phosphorylase. Nucleic Acid Symp. Ser. 1997, 37, 59-60.
15. Walter, M. R.; Cook, W. J.; Cole, L. B.; Short, S. A.; Koszalka, G. W.; Krenitsky, T. A.; Ealick, S. E. Three-dimensional structure of thymidine phosphorylase from Escherichia coli at 2.8 Å resolution. J. Biol. Chem. 1990, 265, 14016-14022.
16. Pugmire, M. J.; Cook, W. J.; Jassanoff, A.; Walter, M. R.; Ealick, S. E. Structural and theoretical studies suggest domain movement produces an active conformation of thymidine phosphorylase. J. Mol. Biol. 1998, 281, 285-299.
17. Pugmire, M. J.; Ealick, S. E. The crystal structure of pyrimidine nucleoside phosphorylase in a closed conformation. Structure, 1998, 6, 1467-1479.
18. (a) Ealick, S. E.; Babu, Y. S.; Bugg, C. E.; Erion, M. D.; Guida, W. C.; Montgomery, J. A.; Secrist, J. A. Application of crystallographic and modelling methods in the design of purine nucleoside phosphorylase inhibitors. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 11540-11544.
19. (b) Guida, W. C.; Elliot, R. D.; Thomas, H. J.; Secrist, J. A., III; Babu, Y. S.; Bugg, C.; Erion, M. D.; Ealick, S. E.; Montgomery, J. A. Structure-based design of inhibitors of purine nucleoside phosphorylase. A study of phosphate mimics. J. Med. Chem. 1994, 37, 1109-1114.
20. (c) Halazy, S.; Erhard, A.; Eggenspiller, A.; Berger-Gross, V.; Danzin, C. Fluorophosphonate derivatives of N9-benzylguanine as potent, slow-binding multisubstrate analogue inhibitors of purine nucleoside phosphorylase. Tetrahedron 1996, 52, 177-184.
21. (d) Kelley, J. L.; McLean, E. W.; Crouch, R. C.; Averett, D. R.; Tuttle, J. V. [[Guaninylalkyl)phosphinico]methyl]phosphinic acids. Multisubstrate analogue inhibitors of human erythrocyte purine nucleoside phosphorylase. J. Med. Chem. 1995, 38, 1005-1014 and references therein.
22. Engel, R. Phosphonates as analogues of natural phosphates. Chem. Rev. 1977, 77, 349-367.
23. Holy, A. Isopolar Phosphorous-Modified Nucleotide Analogues. Adv. Antiviral Drug Des. 1993, 1, 179-231.
24. Itahara, T. NMR and UV study of 1,1'-(α,ω-Alkanediyl)bis-[thymine] and 1,1'-(α,ω-Alkanediyl)bis[uracil]. Bull. Chem. Soc. Jpn. 1997, 70, 2239-2247.
25. Nowick, J. S.; Chen, J. S.; Noronha, G. Molecular recognition in micelles: The roles of hydrogen bonding and hydrophobicity in adenine-thymine base-pairing in SDS micelles. J. Am. Chem. Soc. 1993, 115, 7636-7644.
26. Guibé, F.; Dangles, O.; Balavoine, G.; Loffet, A. Use of an allylic anchor group and its palladium hydrostannolytic cleavage in the solid-phase synthesis of protected peptides fragments. Tetrahedron Lett. 1989, 30, 2641-2644.
27. Phillion, D. P.; Andrews, J. J. Synthesis and reactivity of diethylphosphonomethyl triflate Tetrahedron Lett. 1986, 27, 1477-1480.
28. Jenny, T. F.; Previsani, N.; Benner, S. A. Carbocyclic analogues of nucleosides via modified Mitsunobu reactions. Tetrahedron Lett. 1991, 32, 7029-7032.
29. Cruickshank, K. A.; Jiricny, J.; Reese, C. B. The benzoylation of uracil and thymine. Tetrahedron Lett. 1984, 25, 681-684.
30. For an alternative synthesis of 5, see: Shirokova, E. A.; Tarussova, N. B.; Shipitsin, A. V.; Semizarov, D. G.; Krayevsky, A. A. Novel acyclic nucleotides and nucleoside 5'-triphosphates imitating 2',3'-dideoxy-2',3'-didehydronucleotides: synthesis and biological properties. J. Med. Chem. 1994, 37, 3739-3748.
31. Ashton, W. T.; Canning Meurer, L.; Cantone, Ch. L.; Field, A. K.; Hannah, J.; Karkas, J. D.; Liou, R.; Patel, G. F.; Perry, H. C.; Wagner, A. F.; Walton, E.; Tolman, R. L. Synthesis and antiherpetic activity of (±)-9-[[(Z)-2-hydroxymethyl)cyclopropyl]-methylguanine and related compounds. J. Med. Chem. 1988, 31, 2304-2315.
32. Kelley, J. L.; Kelsey, J. E.; Hall, W. R.; Krochmal, M. P.; Schaeffer, H. J. Pyrimidine Acyclic Nucleosides. 1-[(2-Hydroxyethoxy)methyl]pyrimidines as candidate antivirals. J. Med. Chem. 1981, 24, 753-756.
33. 3-substituted analogues. Synth. Commun. 1988, 18, 931-936.
34. Müller, C. E. Synthesis of 3-substituted 6-aminouracils. Tetrahedron Lett. 1991, 32, 6539-6540.
35. Papesch, V.; Schroeder, E. F. Synthesis of 1-mono and 1,3-disubstituted 6-aminouracil. Diuretic activity. J. Org. Chem. 1951, 36, 3341-3349.
36. Lefebvre, A.; Bernier, J. L.; Lespagnol, Ch. A propos de la structure de pyrimidines obtenues par condensation de lácide cyanacétique et de monoalkylurées. J. Heterocyclic Chem. 1976, 13, 167-168.
37. Perola, E.; Cellai, L.; Brufani, M. Synthesis and activity studies of N-[(ω-N'-(adamant-1-yl)aminoalkyl]-2-(4'-dimethylaminophenyl]acetamides: In the search of selective inhibitors for the different molecular forms of acetylcholinesterase. Bioorg. Med. Chem. Lett. 1998, 8, 575-580.
38. Kansal, V. K.; Huynh-Dinh, T.; Igolen, J. Synthesis of oligodeoxyribonucleotides containing 5'-aminoalkylphosphonates. Tetrahedron Lett. 1988, 29, 5537-5540.
39. Schroeder, E. F. US Patent 2.731.465, 1956 [Chem. Abst. 1957, 51, 1257].
40. West, R. A.; Ledig, K.; Hitchings, G. H. Brit. Patent 812.366, 1959 [Chem. Abst. 1960, 54, 592i].
41. Kochetkova, S. V.; Tsilevich, T. L.; Vladyko, G. V.; Korobchenko, L. V.; Boreko, E. I.; Smirnov, I. P.; Khorlin, A. A.; Gottikh, B. P.; Florentiev, V. L. Compounds related to acyclovir. VII. An approach to designing an antiherpetic agent (6-hydroxy-2-oxahexen-4-yl derivative of nucleic acid bases) Bioorg. Khim. (Russian) 1990, 16, 1362-1368.
42. (a) Esnouf, R. M. Further additions to MolScript version 1.4, including reading and contouring of electron-density maps. Acta Crystallogr. 1999, D55, 938-940.
43. (b) Kraulis, P. J. MOLSCRIPT: A program to produce both detailed and schematic plots of protein structures. J. Appl. Crystallogr. 1991, 24, 946-950.